Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
Pfizer
FEBRUARY 16, 2023
2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Pfizer Disclosure Notice The information contained in this release is as of February 17, 2023.
76 
Let's personalize your content